Tumor biopsies

PROCEDURE8 trials

Sponsors

M.D. Anderson Cancer Center, National University Hospital, Singapore, Dana-Farber Cancer Institute, Institut Curie, National Cancer Institute (NCI)

Conditions

Anal Canal CancerAsian Patients With Advanced Gastro-intestinal Stromal Tumors (GIST) Treated With ImatinibCervical CancerColorectal CancerInflammatory Breast CarcinomaMetastatic Solid TumorsNasopharyngeal CancerNon-small Cell Lung Cancer

Early Phase 1

Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy

CompletedNCT01894451

Dana-Farber Cancer InstituteInflammatory Breast Carcinoma

Start: 2015-06-30End: 2017-03-17Updated: 2019-12-12

Phase 1

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

CompletedNCT03388632

National Cancer Institute (NCI)Metastatic Solid Tumors, Treatment-Refractory Cancers

Start: 2018-02-05End: 2025-05-08Updated: 2025-12-18

Phase 2

MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib

Active, not recruitingNCT03865511

Nantes University HospitalNon-small Cell Lung Cancer

Start: 2019-04-09End: 2025-01-31Updated: 2024-02-28

Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)

CompletedNCT03946358

Centre Hospitalier Universitaire de BesanconAnal Canal Cancer, Cervical Cancer, Squamous Cell Carcinoma of the Head and Neck

Start: 2020-02-18End: 2024-11-01Updated: 2024-12-20

Unknown Phase

DNA Array Analysis of Patients With Cervical Cancer

CompletedNCT00512551

M.D. Anderson Cancer CenterCervical Cancer

Start: 2000-06-20End: 2017-11-20Updated: 2017-11-30

A Study of Lymphangiogenesis in Colorectal and Nasopharyngeal Cancer

National University Hospital, SingaporeColorectal Cancer, Nasopharyngeal Cancer

Start: 2008-07-31End: 2014-12-31Target: 500Updated: 2014-01-22

A Retrospective Study of C-kit Mutation Status in Asian Patients With Advanced Gastro-intestinal Stromal Tumors (GIST) Treated With Imatinib.

National University Hospital, SingaporeAsian Patients With Advanced Gastro-intestinal Stromal Tumors (GIST) Treated With Imatinib

Start: 2011-09-30End: 2014-12-31Updated: 2014-01-22

Biomarker Evaluation in Advanced Stage Cervical Cancer by an International Working Group. Tumor Stages (1B1 - 4)

CompletedNCT02428842

Institut CurieCervical Cancer

Start: 2013-10-24End: 2020-10-20Updated: 2023-01-20

Related Papers

Phase 1 study of recombinant interleukin 15 in combination with nivolumab and ipilimumab in subjects with refractory cancers.

Journal of Clinical Oncology2025-05-28

Methylation, Gene Expression, and Risk Genotypes at the <i>TERT</i>‐<i>CLPTM1L</i> Locus in Cervical Cancer

Molecular Carcinogenesis2024-10-011 citations

Abstract 1755: Integrative genomic and transcriptomic profiles from a prospective cervical cancer study (RAIDs)

Cancer Research2024-03-22

Systematic assessment of tumor necrosis at baseline in cervical cancer - An independent factor associated with poor outcome.

2023-12-201 citations

First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors

Journal for ImmunoTherapy of Cancer2023-10-0122 citations

Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82).

2023-07-2919 citations

A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 TH1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study

Frontiers in Oncology2022-07-1926 citations

Abstract CT147: Phase 1 study of recombinant interleukin 15 (rhIL-15) in combination with checkpoint inhibitors nivolumab and ipilimumab in subjects with refractory cancers

Cancer Research2022-06-151 citations

Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors

Journal for ImmunoTherapy of Cancer2021-11-0143 citations

Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site.

2020-11-1672 citations

Genetic markers and phosphoprotein forms of beta-catenin pβ-Cat552 and pβ-Cat675 are prognostic biomarkers of cervical cancer.

2020-10-209 citations

Abstract 4330: HPV double capture NGS method in cervical cancer: Identification of MACROD2 gene as HPV hot spot integration site and viral load status as a prognostic factor

Cancer Research2020-08-15

IL-15 in the Combination Immunotherapy of Cancer.

2020-05-19183 citations

EP1217 Surgical staging prior to chemoradiation is beneficial for survival in patients with high stage cervical cancer

2019-11-01

Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial.

2019-10-0120 citations

205 PI3K-epigenetic ‘metagene’ alterations were associated with PFS but appear independent of FIGO-2018 stage in cervival patients enrolled in the prospective european bioraids study

2019-09-01

Abstract LB-015: Phase I trial of recombinant human interleukin 15 (rhIL-15) in combination with nivolumab and ipilimumab in refractory cancers

Clinical Research (Excluding Clinical Trials)2019-07-01

Abstract LB-015: Phase I trial of recombinant human interleukin 15 (rhIL-15) in combination with nivolumab and ipilimumab in refractory cancers

Cancer Research2019-07-01

Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome.

2019-04-0235 citations

Molecular profiles as a function of treatment response/progression free survival in a prospective cervical cancer study (RAIDs)

Annals of Oncology2018-10-011 citations

4 more papers not shown